Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Key 2018 bioanalysis and pharmacometrics findings influencing treatment and efficacy include:

  • Co-administration of ivermectin plus dihydroartemisinin-piperaquine leads to increased concentrations of ivermectin, imparting a greater mosquito-lethal effect;
  • In a study in Niger, malnutrition was significantly associated with decreased absorption of lumefantrine, leading to under-exposure and an increased risk of malaria reinfection;
  • Chloroquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine all significantly increase plasma primaquine concentrations; and
  • In TB modelling and simulation showed inadequate rifampicin drug levels in children with the currently available dosing regimens, and the developed population pharmacokinetic model was used to suggest an optimised dose regimen.